Effectiveness of complete primary vaccination against COVID-19 at primary care and community level during predominant Delta circulation in Europe: multicentre analysis, I-MOVE-COVID-19 and ECDC networks, July to August 2021

I-MOVE-COVID-19 primary care study team, ECDC primary care study team, Esther Kissling*, Mariette Hooiveld, Ivan Martinez-Baz, Clara Mazagatos, Naoma William, Ana Maria Vilcu, Marjolein N. Kooijman, Maja Ilic, Lisa Domegan, Ausenda Machado, Simon De Lusignan, Mihaela Lazar, Adam Meijer, Mia Brytting, Itziar Casado, Amparo Larrauri, Josephine L.K. Murray, Sylvie BehillilBrechje De Gier, Ivan Mlinaric, Joan O'Donnell, Ana Paula Rodrigues, Ruby Tsang, Olivia Timnea, Marit De Lange, Maximilian Riess, Jesus Castilla, Francisco Pozo, Mark Hamilton, Alessandra Falchi, Mirjam J. Knol, Sanja Kurecic Filipovic, Linda Dunford, Raquel Guiomar, Jade Cogdale, Carmen Cherciu, Tessa Jansen, Theresa Enkirch, Luca Basile, Jeff Connell, Veronica Gomez, Virginia Sandonis Martin, Sabrina Bacci, Angela M.C. Rose, Lucia Pastore Celentano, Marta Valenciano

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

12 Citations (Scopus)
15 Downloads (Pure)

Abstract

Introduction: In July and August 2021, the SARS-CoV-2 Delta variant dominated in Europe. 

Aim: Using a multicentre test-negative study, we measured COVID-19 vaccine effectiveness (VE) against symptomatic infection. 

Methods: Individuals with COVID-19 or acute respiratory symptoms at primary care/community level in 10 European countries were tested for SARS-CoV-2. We measured complete primary course overall VE by vaccine brand and by time since vaccination. 

Results: Overall VE was 74% (95% CI: 69-79), 76% (95% CI: 71-80), 63% (95% CI: 48-75) and 63% (95% CI: 16-83) among those aged 30-44, 45-59, 60-74 and ≥ 75 years, respectively. VE among those aged 30-59 years was 78% (95% CI: 75-81), 66% (95% CI: 58-73), 91% (95% CI: 87-94) and 52% (95% CI: 40-61), for Comirnaty, Vaxzevria, Spikevax and COVID-19 Vaccine Janssen, respectively. VE among people 60 years and older was 67% (95% CI: 52-77), 65% (95% CI: 48-76) and 83% (95% CI: 64-92) for Comirnaty, Vaxzevria and Spikevax, respectively. Comirnaty VE among those aged 30-59 years was 87% (95% CI: 83-89) at 14-29 days and 65% (95% CI: 56-71%) at ≥ 90 days between vaccination and onset of symptoms. 

Conclusions: VE against symptomatic infection with the SARS-CoV-2 Delta variant varied among brands, ranging from 52% to 91%. While some waning of the vaccine effect may be present (sample size limited this analysis to only Comirnaty), protection was 65% at 90 days or more between vaccination and onset.

Original languageEnglish
JournalEurosurveillance
Volume27
Issue number21
DOIs
Publication statusPublished - 26 May 2022

Bibliographical note

Funding Information: This project has received funding from the European Union’s
Horizon 2020 research and innovation programme under grant agreement No 101003673.
This project received funding from the European Centre for Disease Prevention and Control (ECDC) under the contract ECD.11486.
Professor de Lusignan has received grants not directly relating to this work, from AstraZeneca, GSK, Sanofi, Seqirus and Takeda for vaccine-related research and has been a member of advisory boards for AstraZeneca, Sanofi and Seqirus.

Open Access: This is an open-access article distributed under the terms of the Creative Commons Attribution (CC BY 4.0) Licence. You may share and adapt the material, but must give appropriate credit to the source, provide a link to the licence and indicate if changes were made.

Publisher Copyright: This article is copyright of the authors or their affiliated institutions, 2022.

Citation: Kissling Esther, Hooiveld Mariëtte, Martínez-Baz Iván, Mazagatos Clara, William Naoma, Vilcu Ana-Maria, Kooijman Marjolein N, Ilić Maja, Domegan Lisa, Machado Ausenda, de Lusignan Simon, Lazar Mihaela, Meijer Adam, Brytting Mia, Casado Itziar, Larrauri Amparo, Murray Josephine-L K, Behillil Sylvie, de Gier Brechje, Mlinarić Ivan, O’Donnell Joan, Rodrigues Ana Paula, Tsang Ruby, Timnea Olivia, de Lange Marit, Riess Maximilian, Castilla Jesús, Pozo Francisco, Hamilton Mark, Falchi Alessandra, Knol Mirjam J, Kurečić Filipović Sanja, Dunford Linda, Guiomar Raquel, Cogdale Jade, Cherciu Carmen, Jansen Tessa, Enkirch Theresa, Basile Luca, Connell Jeff, Gomez Verónica, Sandonis Martín Virginia, Bacci Sabrina, Rose Angela MC, Pastore Celentano Lucia, Valenciano Marta, I-MOVE-COVID-19
and ECDC primary care study teams. Effectiveness of complete primary vaccination against COVID-19 at primary care and community level during predominant Delta circulation in Europe: multicentre analysis, I-MOVE-COVID-19 and ECDC networks, July to August 2021. Euro Surveill. 2022;27(21):pii=2101104. https://doi.org/10.2807/1560-7917.ES.2022.27.21.2101104

DOI: https://doi.org/10.2807/1560-7917.ES.2022.27.21.2101104

Fingerprint

Dive into the research topics of 'Effectiveness of complete primary vaccination against COVID-19 at primary care and community level during predominant Delta circulation in Europe: multicentre analysis, I-MOVE-COVID-19 and ECDC networks, July to August 2021'. Together they form a unique fingerprint.

Cite this